221 related articles for article (PubMed ID: 24692694)
41. Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells.
Takagaki K; Katsuma S; Kaminishi Y; Horio T; Nakagawa S; Tanaka T; Ohgi T; Yano J
J Biochem; 2004 Nov; 136(5):733-40. PubMed ID: 15632314
[TBL] [Abstract][Full Text] [Related]
42. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
Xie C; Edwards H; Lograsso SB; Buck SA; Matherly LH; Taub JW; Ge Y
Pediatr Blood Cancer; 2012 Dec; 59(7):1245-51. PubMed ID: 22488775
[TBL] [Abstract][Full Text] [Related]
43. Potential mechanisms of resistance to cytarabine in AML patients.
Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
Gandhi V; Kantarjian H; Faderl S; Bonate P; Du M; Ayres M; Rios MB; Keating MJ; Plunkett W
Clin Cancer Res; 2003 Dec; 9(17):6335-42. PubMed ID: 14695132
[TBL] [Abstract][Full Text] [Related]
45. CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
Anderson E; Mehta P; Heywood J; Rees B; Bone H; Robinson G; Reynolds D; Salisbury V; Mayer L
Leuk Res; 2018 Nov; 74():121-129. PubMed ID: 30119908
[TBL] [Abstract][Full Text] [Related]
46. Genetic factors influencing cytarabine therapy.
Lamba JK
Pharmacogenomics; 2009 Oct; 10(10):1657-74. PubMed ID: 19842938
[TBL] [Abstract][Full Text] [Related]
47. Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity.
Hubeek I; Peters GJ; Broekhuizen AJ; Talianidis I; Schouten van Meeteren AY; van Wering ER; Gibson B; Creutzig U; Kaspers GJ
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1351-6. PubMed ID: 15571257
[TBL] [Abstract][Full Text] [Related]
48. The role of clofarabine in acute myeloid leukemia.
Ghanem H; Kantarjian H; Ohanian M; Jabbour E
Leuk Lymphoma; 2013 Apr; 54(4):688-98. PubMed ID: 22957815
[TBL] [Abstract][Full Text] [Related]
49. Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines.
Rathe SK; Largaespada DA
Leukemia; 2010 Aug; 24(8):1513-5. PubMed ID: 20508618
[No Abstract] [Full Text] [Related]
50. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
BMC Cancer; 2014 Jul; 14():547. PubMed ID: 25070259
[TBL] [Abstract][Full Text] [Related]
51. Determination of clofarabine triphosphate concentrations in leukemia cells using sensitive, isocratic high-performance liquid chromatography.
Yamauchi T; Nishi R; Ueda T
Anticancer Res; 2011 Sep; 31(9):2863-7. PubMed ID: 21868530
[TBL] [Abstract][Full Text] [Related]
52. [Ara-c induced apoptosis in human myeloid leukemia cell line HL-60].
Zhou J; Chen Y; Li C
Zhonghua Zhong Liu Za Zhi; 1997 Mar; 19(2):107-10. PubMed ID: 10743072
[TBL] [Abstract][Full Text] [Related]
53. Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells.
Sarkar M; Han T; Damaraju V; Carpenter P; Cass CE; Agarwal RP
Biochem Pharmacol; 2005 Aug; 70(3):426-32. PubMed ID: 15950950
[TBL] [Abstract][Full Text] [Related]
54. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia.
Alloush HM; Anderson E; Martin AD; Ruddock MW; Angell JE; Hill PJ; Mehta P; Smith MA; Smith JG; Salisbury VC
Clin Chem; 2010 Dec; 56(12):1862-70. PubMed ID: 20921267
[TBL] [Abstract][Full Text] [Related]
55. Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.
Yamauchi T; Uzui K; Shigemi H; Negoro E; Yoshida A; Ueda T
Cancer Sci; 2013 Jul; 104(7):926-33. PubMed ID: 23557198
[TBL] [Abstract][Full Text] [Related]
56. The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation.
Zhang Y; Secrist JA; Ealick SE
Acta Crystallogr D Biol Crystallogr; 2006 Feb; 62(Pt 2):133-9. PubMed ID: 16421443
[TBL] [Abstract][Full Text] [Related]
57. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
[TBL] [Abstract][Full Text] [Related]
58. Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.
Macanas-Pirard P; Broekhuizen R; González A; Oyanadel C; Ernst D; García P; Montecinos VP; Court F; Ocqueteau M; Ramirez P; Nervi B
Oncotarget; 2017 Apr; 8(14):23073-23086. PubMed ID: 28160570
[TBL] [Abstract][Full Text] [Related]
59. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
Lamba JK; Crews K; Pounds S; Schuetz EG; Gresham J; Gandhi V; Plunkett W; Rubnitz J; Ribeiro R
J Pharmacol Exp Ther; 2007 Dec; 323(3):935-45. PubMed ID: 17855478
[TBL] [Abstract][Full Text] [Related]
60. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
